7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A board-reviewed clinical guide to managing adverse events from GHRH analogs (sermorelin, tesamorelin, CJC-1295, ipamorelin). Covers injection-site reactions, water retention, glucose dysregulation, and monitoring protocols with primary-source citations.
A prescriber-level guide to billing codes, payer policies, prior-authorization workflows, and appeals strategies for GHRH analog peptides including sermorelin, tesamorelin, and CJC-1295.
A prescriber-level monograph covering the GHRH analog drug class: mechanism, pharmacokinetics, approved agents, clinical evidence, dosing protocols, safety, and monitoring for sermorelin, tesamorelin, and related compounds.
A board-reviewed prescriber guide to the GHRH analog drug class covering sermorelin, tesamorelin, and CJC-1295. Includes baseline labs, on-therapy monitoring intervals, dose-adjustment criteria, and safety thresholds with primary-source citations.
A prescriber-level review of GHRH analogs (sermorelin, tesamorelin, CJC-1295) across special populations including pediatrics, older adults, renal and hepatic impairment, and pregnancy. Covers dosing, safety signals, and clinical decision points.
An evidence-based guide to tesamorelin dosing, monitoring, and discontinuation, plus what is and is not established for sermorelin and CJC-1295.
A clinical guide to GHRH analog selection, sermorelin, tesamorelin, CJC-1295, and modified peptides, covering pharmacology, dosing, indications, and how to choose between agents for GH axis stimulation.